In vivo efficacy of Meropenem/Nacubactam combination against in vitro-generated resistant mutants

Nacubactam (NAC) is a novel diazabicyclooctane with dual activity as a ß-lactamase inhibitor and as a direct-acting antibiotic. The combination of Meropenem (MEM) and NAC is active against carbapenem-resistant Enterobacteriaceae isolates expressing KPC, OXA-48 and metallo β-lactamases.

The objective of the reported study was to assess potential in vivo fitness costs associated with resistance by determining in vivo efficacy of MEM/NAC against in vitro generated mutants.

Recently presented by our experts in collaboration with Roche Pharma at the ECCMID 2018 conference, download your copy of the scientific poster today and discover more!

In vivo efficacy of Meropenem/Nacubactam combination against in vitro-generated resistant mutants

Get your copy today!

Download our poster now